LXRXLexicon Pharmaceuticals, Inc.
$1.67+40% 1Y
$1.67
$1.1452 weeks$2.50
The financials
Lexicon Pharmaceuticals, Inc. by the numbers
Lexicon Pharmaceuticals, Inc. (LXRX) reported revenue of $692K in Q2 2026 (quarter ended Jun 30, 2026), down 98% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $32M. For the full year FY2025, revenue was $50M (+60% year on year) and net income −$50M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $692K | $29M | −98% |
| Gross profit | $653K | $29M | −98% |
| Operating income | −$27M | $3.7M | to a loss |
| Net income | −$32M | $3.3M | to a loss |
| Diluted EPS | −$0.07 | $0.01 | to a loss |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00 (-100%)
License grew -100% year on year
Segment Latestquarter on quarteryear on year
- License$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%